Cardiometabolic Benefits and Risk-Related Markers Cagrilintide research also extends to cardiometabolic biology, especially where researchers are interested in the relationship between weight-related signaling, glycemic control, and broader metabolic risk markers
For a clear outside reference, clinical researchers reporting that women in menopause benefit from GLP-1 weight loss medications as much as younger women is worth reading
55 Empagliflozin Drugs and Lactation Database (2023)
Dont combine unlicensed retatrutide with a prescribed GLP-1 medication
The American Diabetes Association (ADA) recognizes the cardiovascular benefits of GLP-1 receptor agonists in their Standards of Care but does not currently recommend these agents solely for inflammation management outside established indications for diabetes, obesity, or cardiovascular risk reduction
5 When unresolved, these chronic inflammatory components directly cause hepatic damage, overwhelm innate hepatic regeneration, and lead to fibrosis, cirrhosis, and hepatocarcinogenesis